Literature DB >> 10378255

Group testing in presence of classification errors.

D Gupta1, R Malina.   

Abstract

We modify Dorfman's and Sterrett's group testing protocols to make them suitable for testing blood samples for the presence of HIV antibodies, as well as for many industrial applications, when false negatives cannot be tolerated. We first propose that test kit sensitivity be increased to nearly 100 per cent by altering the reactive versus non-reactive threshold. Subsequently, group and repeat testing are used with a careful selection of group size and the number of times a test is repeated, in order to maximize efficiency while keeping the false positive predictive value (FPPV) within a specified limit. Numerical calculations show that our testing protocol is efficient, has low procedural complexity and keeps both types of classification errors below specified tolerance limits.

Mesh:

Substances:

Year:  1999        PMID: 10378255     DOI: 10.1002/(sici)1097-0258(19990515)18:9<1049::aid-sim105>3.0.co;2-z

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests.

Authors:  Daniel J Westreich; Michael G Hudgens; Susan A Fiscus; Christopher D Pilcher
Journal:  J Clin Microbiol       Date:  2008-03-19       Impact factor: 5.948

2.  Group testing in heterogeneous populations by using halving algorithms.

Authors:  Michael S Black; Christopher R Bilder; Joshua M Tebbs
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2012-03-01       Impact factor: 1.864

3.  Is group testing ready for prime-time in disease identification?

Authors:  Gregory Haber; Yaakov Malinovsky; Paul S Albert
Journal:  Stat Med       Date:  2021-04-28       Impact factor: 2.497

4.  Pooled testing of traced contacts under superspreading dynamics.

Authors:  Stratis Tsirtsis; Abir De; Lars Lorch; Manuel Gomez-Rodriguez
Journal:  PLoS Comput Biol       Date:  2022-03-28       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.